OXFORD, Miss., July 11, 2007 (PRIME NEWSWIRE) -- Modern Technology Corp (Pink Sheets:MODC), a bioscience technology development and acquisition company, announced today Dr. Marc Rose of VitalCare and medical advisor to the Life Extension Foundation will submit information about AnuCyte for review and future write-up in Life Extension Magazine. The publication of these articles is part of the agreement between the Company and VitalCare as part of our continuing effort to promote and create market awareness of the service. The Life Extension Foundation is a nonprofit organization, whose long-range goal is the radical extension of the healthy human lifespan. In seeking to control aging, the Foundation's objective is to develop methods to enable people to live in health, youth and vigor for unlimited periods of time. The Life Extension Foundation was officially incorporated in 1980, but the founders have been involved in anti-aging research since the 1960's.
The Life Extension Foundation is the largest organization dedicated to investigating every method of extending the healthy human life span.
Anthony Welch, Chairman, said: "We believe the AnuCyte Cancer Detection System is unique and more accurate than any other method of cancer detection. It has an effective 100% negative predicative value for cancer or pre-cancer in any tested sample and has an effective 100% accuracy rate at detecting cancer or pre-cancer within a sample. These are powerful numbers, well beyond the accuracy rate of any other known test and is of great interest to healthcare publications. We applaud Dr. Rose's plans for creating greater awareness of our service."
Dr. Marc Rose, Co-Founder of VitalCare said, "Early detection of cancer is key to survival. The AnuCyte system and its incredible accuracy bring an unprecedented level of early detection potential to the healthcare market."
About the AnuCyte Cancer Detection System
The AnuCyte Cancer Detection System is an automated machine used to detect the presence of cancer in cell samples. The system accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test within the same sample. The system is designed based on the chromosomal imbalance theory of cancer. Over the prior ten years the chromosomal imbalance theory of cancer has been proven correct both experimentally and theoretically in numerous, rigorously peer-reviewed publications in the leading journals. The system's accuracy in detecting the presence or absence of cancer is effectively 100%.
About Modern Technology Corp
Modern Technology Corp, a bioscience technology development and acquisition company, builds revenues through a model of continuous growth, strategic acquisitions, and commercialization of nascent technology. The Company files reports with the U.S. Securities and Exchange Commission. For the company's filings, visit http://www.sec.gov.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.